This is a single-center, open-label, randomized, controlled, exploratory clinical trial designed to evaluate the efficacy and safety of de-escalated surgery compared with standard surgery in patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who achieved a partial response (PR) or complete response (CR) after neoadjuvant immunochemotherapy. Eligible patients will be randomly assigned in a 1:1 ratio to either the de-escalated surgery group (experimental) or the standard surgery group (control). The de-escalated surgery group will undergo limited tumor res
For full eligibility, visit ClinicalTrials.gov.
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Head and Neck Cancer Trials on Trialify →